"...please spare us the rhetoric of ramping up communication etc, etc if you don't intend to follow through with it."
Agreed. Since appointing Dr Ian Dixon ED last November, directors had opportunities to share their resuscitation plans when posting the December quarter 4c report and then the half yearly report. They chose not to.
Next month they'll report on the March quarter.
It would be good if they could identify members of the new scientific/medical advisory panel, list recommendations made by the panel and detail any plans for cranking the syringe relationship with Sol Millennium, Shanghai.
Let's trust the board can demonstrate enthusiasm - even passion - for Medigard and its prospects.
Otherwise, the MC may remain near the lowly level of $2.38m.
MGZ Price at posting:
1.9¢ Sentiment: None Disclosure: Held
